Citations

Clear

68 citation(s) found for "Kingsley, Ed".

Acanthamoebic Meningoencephalitis: Lessons in Avoiding a Postmortem Diagnosis
Parisi, Joseph E. , Scheithauer, Bernd W., Kingsley, Thomas C. , Jansen, Robert D., Pritt, Bobbi S.

Mayo Clinic

The FASEB Journal | April 10, 2020 | Volume: 21 | Issue: 5 | Pages: No page available

10.1096/fasebj.21.5.a403 Get It

A 38‐year‐old woman, status‐post renal transplant on immunosuppressive therapy, presented with fever, hypotension, and painful erythematous nodules on her chest, abdomen, and back. Skin biopsy revealed panniculitis with fat necrosis, and corresponding cultures showed no growth. Over the next 5 days, she became obtunded and developed a left hemiparesis. MRI showed non‐enhancing bilateral lesions in the cerebral cortex. She deteriorated and died. At autopsy, the 954 gram brain demonstrated flattened gyri and multiple disseminated necrotic foci. Microscopically, numerous cysts and trophozoites were identified within necrotic foci, consistent with Acanthamoeba spp. Review of the skin biopsy revealed similar organisms. Unlike primary amebic meningoencephalitis in healthy children and young adults caused by Naglearia fowlerii, encephalitis due to Acanthamoeba spp. is a subacute, progressive disease of immunocompromised patients. The double‐walled, cysts of Acanthamoeba spp. stain with H&E and Gomori Methenamine Silver, and may be mistaken for a fungus. Knowledge of the epidemiology and microscopic appearance of Acanthamoeba spp. is essential for accurate and timely diagnosis of this serious and potentially treatable infection.
360 Contemporary Diagnostic Evaluation of Traumatic Penile Injuries
Houlihan, Matthew, Fakhoury, M., Stroie, Florian A., Köhler, Tobias , Hollowell, Courtney M.P. , Kingsley, Samuel

Mayo Clinic

The Journal of Sexual Medicine | January 1, 2020 | Volume: 17 | Issue: Supplement_1 | Pages: S97-S97

10.1016/j.jsxm.2019.11.180 Get It

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
Yasenchak, Christopher A. , Burke, John M. , Fayad, Luis , Holkova, Beata , Knapp, Mark, Ansell, Stephen M. , Patel‐Donnelly, Dipti, Yimer, Habte, Smith, Scott E. , Levy, Moshe , Seetharam, ­Mahesh , Kingsley, Edwin, Klein, Leonard M., Wagner‐Johnston, Nina, Ruffner, Katherine, Budde, Lihua E. , Halwani, Ahmad , Farber, Charles Michael , Kolibaba, Kathryn S. , Advani, Ranjana H. , Belada, David , Brooks, Donald , Bartlett, Nancy L.

Mayo Clinic

Blood | November 17, 2019 | Volume: 128 | Issue: 22 | Pages: 104-104

10.1182/blood.v128.22.104.104 Get It

Abstract Introduction DLBCL is the most common lymphoid neoplasm in adults (Swerdlow 2016). While durable CRs are achieved in approximately 70% of patients (pts) with frontline RCHOP therapy (Pfreundschuh 2008), pts with high-risk features often experience disease resistance or relapse. In Part 1 of an ongoing study, pts with high-intermediate or high risk DLBCL by international prognostic index (IPI) scores, regardless of CD30 expression by IHC, were treated with 1.2 or 1.8 mg/kg brentuximab vedotin (BV) combined with RCHOP. After 3 of the first 10 pts treated at 1.8 mg/kg BV+RCHOP developed Grade 3 peripheral neuropathy (per Standardized MedDRA Query [SMQ]), all pts enrolled subsequently received treatment with 1.2 mg/kg BV+RCHOP. Following completion of enrollment in Part 1, the protocol was amended to enroll a non-randomized portion of the study (Part 2) evaluating the safety and efficacy of 1.8 mg/kg BV+RCHP (Yasenchak 2015), followed by an open-label, randomized portion comparing BV+RCHP to RCHOP (Part 3). Initial results from Part 2 and updated results from Part 1 are reported here. Methods For Part 2 of the study, pts with CD30-expressing high-intermediate and high-risk DLBCL were treated with up to 6 cycles of 1.8 mg/kg BV+RCHP (NCT01925612). Key inclusion criteria were CD30 expression by IHC performed by a local pathology lab and standard IPI scores of 3-5 or age-adjusted IPI (aaIPI) scores of 2-3 (high-intermediate/high risk). CD30 expression was confirmed by a central pathology lab, although CD30 expression by local pathology lab was required for eligibility. Disease response was evaluated with PET/CT per Cheson 2007. Results At the time of analysis for this ongoing study, 11 pts in Part 2 were treated with BV+RCHP (7 male, 4 female; 22-78 yrs). Of these pts, 9 had high-intermediate risk (IPI 3, aaIPI 2) and 2 had high risk disease (IPI 4-5, aaIPI 3), 6 had Stage IV disease, and 6 had an ECOG score of 2. At the end of treatment, the overall response rate was 91% (9 CR, 1 PR); 1 pt had PD after Cycle 4. The most frequent (>20%) treatment-emergent adverse events (AEs) were alopecia and nausea (73% each); fatigue (64%); constipation and peripheral sensory neuropathy (55% each); neutropenia and throat irritation (36% each); and chills, diarrhea, headache, and stomatitis (27% each). Grade 3 or 4 AEs occurred in 8 pts and 5 pts had serious AEs, which included febrile neutropenia, bacteremia, nausea, pneumocystis jiroveci pneumonia, pulmonary embolism, and vomiting. Peripheral sensory neuropathy occurred in 6 pts and all were Grade 1 or 2 events; no peripheral motor neuropathy AEs were reported. No AEs were fatal or led to discontinuation. One pt discontinued treatment after Cycle 4 due to disease progression. For the first 51 pts in Part 1, the progression-free survival (PFS) at 18 months for pts with CD30 expression (25 pts) or without detectable CD30 expression (24 pts) by IHC was 79% (95% CI: 57%, 91%) versus 58% (95% CI: 36%, 75%), respectively. Overall survival for pts was 92% (95% CI: 71%, 98%) versus 71% (95% CI: 48%, 85%), respectively. Ten pts had pre-existing peripheral neuropathy (per SMQ) at study entry. Treatment-emergent peripheral neuropathy (per SMQ) was observed in 75% of pts (38/51) who received BV+RCHOP; 55% of these pts (21/38) had resolution of all or some peripheral neuropathy events. Conclusions 1.8 mg/kg BV+RCHP is active as frontline treatment in CD30-expressing, high-intermediate/high risk DLBCL. When combined with RCHP, 1.8 mg/kg BV appears to be well-tolerated. The PFS and OS for pts with CD30-expression who received BV+RCHOP appear promising. The study is currently ongoing in pts with CD30-expressing high-intermediate/high risk DLBCL to assess the safety and activity of 1.8 mg/kg BV+RCHP versus standard RCHOP. Disclosures Halwani: Bristol Myers-Squibb: Research Funding; Kyowa Hakko Kirin: Research Funding; Takeda: Research Funding; Genentech: Research Funding; AbbVie: Consultancy, Other: Travel Expenses, Research Funding; Seattle Genetics: Consultancy, Research Funding; Immune Design: Research Funding; Miragen: Research Funding; Pharmacyclics: Consultancy; Amgen: Research Funding. Yasenchak:Seattle Genetics: Research Funding. Farber:Seattle Genetics: Research Funding. Burke:Pfizer: Consultancy; Janssen: Consultancy; Incyte: Consultancy; TG Therapeutics: Other: Travel Expenses; Millenium: Consultancy. Fayad:Seattle Genetics: Consultancy, Research Funding. Holkova:Seattle Genetics: Research Funding. Knapp:Insys Therapeutics, Inc.: Consultancy, Other: Travel, Accommodations, Expenses; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding. Kolibaba:Gilead: Consultancy, Research Funding; Celgene: Research Funding; TG Therapeutics: Research Funding; Takeda Pharmaceuticals International Co.: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Research Funding; janssen: Research Funding; GSK: Research Funding; Genentech: Research Funding; Acerta: Research Funding. Patel-Donnelly:Seattle Genetics: Research Funding. Yimer:Ariad Pharmaceuticals: Consultancy; Biotheranostics: Consultancy; Bluebird Bio: Equity Ownership; Kite Pharma: Equity Ownership; Clovis Oncology: Equity Ownership; Juno Therpeutics: Equity Ownership; Seattle Genetics: Research Funding. Smith:Celgene: Consultancy, Speakers Bureau; Seattle Genetics: Research Funding. Levy:Janssen: Speakers Bureau; Amgen: Speakers Bureau; Takeda Pharmaceuticals International Co.: Speakers Bureau; Seattle Genetics: Research Funding; Actinium Pharmaceuticals, Inc.: Research Funding. Seetharam:Seattle Genetics: Research Funding. Belada:Seattle Genetics: Research Funding. Brooks:Seattle Genetics: Research Funding. Kingsley:Gilead: Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Equity Ownership. Wagner-Johnston:Seattle Genetics: Research Funding. Ruffner:Forma Therapeutics: Consultancy; Sydnax: Consultancy; Seattle Genetics: Employment, Equity Ownership; Array Biopharma: Employment; Medivation: Employment. Bartlett:Gilead: Consultancy.
Bone Research Society Abstracts
Team, the ERC ADREEM, Roelofs, Anke J. , Cummings, Steven R. , Bhimjiyani, A. , Neuburger, Jenny , Gregson, Celia L, Sparkes, Penny C. , Swiatkowska, Agnes, Lelliott, Christopher J. , Williams, Graham R. , Bassett, J. H. Duncan , Paton‐Hough, Julia, Tazzyman, Simon , Evans, Holly , Lath, Darren , Down, Jenny , Green, Alanna, Snowden, John A. , Chantry, Andrew, Na, Harvey, Shepstone, Lee , Kanis, John А. , Lenaghan, Elizabeth, Clarke, Shane, Harvey, I., Heawood, Ali, Howe, Amanda , Marshall, Tarnya, McCloskey, Eugène , Group, the SCOOP Trial, Hardy, Rebecca , Adams, Judith E., Aspden, Richard, Js, Gregory , Vlachopoulo, Dimitris, Maslin, Kate , Gossiel, Fatma , Bishop, Nicholas , Fraser, Robert, Gandhi, Saurabh , Prentice, Ann , Schoenmakers, Inez , Eastell, Richard , Cooper, Cyrus, Group, the MAVIDOS Trial, Ward, Kate, Cooper, Cyrus, Dennison, Elaine, Bonnet, Cleo, Eccles, Emily, Norman, K. Duane, Ko, Jeong‐Hun, Williams, G. Rhys, Madhusudan, Namrata, Bountra, C. , Oppermann, Udo , Oreffo, Richard OC , McEwan, Josephine, White, Kate L. , Oreffo, Richard, Dunlop, D. , Cornish, Jillian , Goring, Alice, Boyde, A. , Hesse, Eric , Olsen, Björn, Pitsilides, Andrew, Oreffo, Richard, Hartley, A M, Fraser, William, Tobias, JS, Harvey, Nicolas, Johansson, Helena , Cooper, Cyrus, Team, SCOOP Study, Roberts, Fiona , Rashdan, Nabil A. , Staines, Katherine, Milne, Elspeth , Morton, Nicholas M. , McCulloch, Kendal, Dunning, Lynette, Lockhart, John C. , Thomas, Neil Peter, Ranganath, L. , Gallagher, James A., Ward, Kate, Stewart, Angela, Garratt, Liz, Bastin, Sonja , Gamble, Gregory D., Shaw, Nick , Prieto-Alhambra, D, Cooper, Cyrus, Hughes, Juliette H. , Liu, Ke , Hughes, Andrew, Nijjar, Jagtar Singh , Padley, Jessica, Poole, Ken, Litwic, Anna, Dennison, Elaine, Edwards, Mark H. , Cooper, Cyrus, Dennison, Elaine, Ishimoto, Yuyu , Cooper, Cyrus, Ntani, Georgia , Yamada, H. , Muraki, Shigeyuki , Yoshida, Munehito , Yoshimura, Tan, Juan, Poole, Kenneth, Larrouture, Quitterie C. , Athanasou, Nick, Al-Sari, Usama , Felder, Alessandro , Chua, Melissa Y, Lodhia, Kalyani, Kłosowski, Michał M. , Farquharson, Colin, Inglis, Stefanie , Redl, Heinz , Oreffo, Richard, Gogakos, Apostolos , Ebri, Davide Komla, Pipelines, Sanger Mouse, Cidonio, Gianluca , Lanham, Stuart , Dawson, Jonathan, Oreffo, Richard, McEwan, Josephine, Wells, Julia, Oka, Hiroyuki , Iidaka, Toshiko , Kodama, Rie , Horii, Chiaki , Nakamura, Kozo, Akune, Toru, Hudson, Katie, Fisher, Matt , Chantry, Andrew, Adoum, Anne‐Tounsia, Bassett, Duncan, Mannan, Naila S., Dewhurst, Hannah F. , Ghirardello, Elena J. , Pipelines, Sangar Mouse, Komla‐Ebri, David, Curry, Katharine F., 𠀉, JH, Ganguly, Payal , Sparkes, Penny, Curry, Katherine F., Sim, Alisia, Kaczynski, Jakub , Novak, Amanda , Mills, David , Bonnet, Cleo, Ihenacho, Menna, Cronin, Rose‐Marie, Mason, Debbie , Rodriguez, Alexander, Xu, Cecilia, Scott, David , Dennison, Elaine, Stephenson, Sonya, Cosulich, Carlotta, Cooper, Cyrus, Sano, Hiroshige, Kondo, Naoki , Shimakura, Taketoshi, Fujisawa, Junichi, Kijima, Yasufumi, Skingle, Linda , Yamamoto, Noriaki , Takahashi, Hideaki E. , Endo, Naoto , Beamish, Rebecca, Evans, Sam, Morgan, Stephanie , Hooper, Kirsty M. , Halewood, Katherine , Stevens, Craig , Staines, Katherine, Steenhuis, Pieter, Ignelzi, Michael A., Morris, Michael D., Karabetsos, Matthew, VanRenterghem, Gloria, Ayyalusamy, Ramamoorthy, Kadamban, Premila, Vaughan‐Lane, Timothy, Wright, Maria da Glória Miotto , Poole, Kenneth , Cooper, Cyrus, Neven, Ellen, Wheeler‐Jones, Caroline , Rukuni, Ruramayi , Crabtree, Nicola , Mukwasi, Cynthia, McHugh, Grace , Gregson, Celia L, Luo, Jin , Dodhia, Vikash , Czekanska, Ewa M., Oreffo, Richard, Arnold, Emily L. , Gohin, Stéphanie , Soper, Robin, Ytrebø, Lars Marius , Meeson, Richard , Howat, D. , Hodges, Stephen , Evelyn‐Wright, Stephanie , Mavrogordato, Mark , Rankin, Kathryn , Stocks, Oliver, Hartley, Chris , Kerslake, R. W. , Thomson, Seamus , Muderis, Munjed Al, Ward, Kevin R. , Sowman, Aneka, Hart, Deborah , Spector, Tim D. , Coxon, Joshua, Townsend, Paul , Jones, Rebecca , Lawrence, Kevin M., Egan, B. T., Tattersall, Luke , Holm, Stefan H. , Martin, Jenny, Saunders, Fiona, Martin, J F, Saunders, Fiona, Davies, Amanda, Hugtenburg, R.P. , Wintsch, Emma, Anderson, Susan, Alshamrani, Hassan A. , Paggiosi, Margaret , Bishop, Nick , Offiah, Amaka C , Pretorius, Sarah, Roberts, Scott, Logan, Malcolm , Allaire, Brett , Bouxsein, Mary , Olatokun, Olamide, Nash, Thomas H., Abdul-Jabar, Hani B., Tran, Anh Nhi, Segeletz, Sandra, McDermott, Emma, Wileman, Tom, Helfrich, Miep , Redman, Amelia, Elford, Carole, Evans, Bronwen, Bradley, Mark , Martín, Iván , Khosla, Sundeep , Mahajan, Sumeet , Heller, Markus O.W. , Schneider, Philipp , Bonewald, Lynda F. , Lillycrop, Karen A. , Hanson, Mark, Lord, Janet M. , Maes, Christa , Ben‐Shlomo, Yoav , Leitch, Victoria D. , Logan, John G. , Croucher, Peter Ian , Lawson, Michelle Anne , Chantry, Andrew , Parsons, Camille M. , Fordham, Richard J , Gittoes, Neil , Holland, Richard , Redmond, Niamh Maria , Peters, T. J. , Torgerson, David John , O’Neill, Terence W , Cooper, Cyrus , Ireland, Alex , Muthuri, Stella G. , Saunders, Fiona R. , Pavlova, Anastasia Vladimirovna , Martin, Kathryn Remmes , Barr, Rebecca J. , Kuh, Diana J. , Cooper, Rachel , BARKER, ALAN ROBERT , Ubago‐Guisado, Esther , Williams, Craig Anthony , Gracia‐Marco, Luis , Curtis, Elizabeth Mary , D’Angelo, Stefania , Moon, Rebecca Jane , Crozier, Sarah , Kennedy, Stephen , Papageorghiou, Aris T. , Fraser, Robert, Inskip, Hazel M. , Godfrey, Keith M. , Javaid, M K , Cooper, Cyrus, Harvey, Nicholas C. , Group, the MAVIDOS Trial, Fuggle, Nicholas R. , Westbury, Leo D. , Syddall, Holly Emma , Ward, Kate, Duggal, Niharika Arora , Bonnet, Cleo Selina , Gilbert, Sophie J. , Norman, Kingsley, Mason, Deborah J. , Pereira, Marie , Petretto, Enrico , Williams, Graham R, Behmoaras, Jacques V. , Andrés, María C. de , Goriainov, Vitali , McEwan, Josephine K, White, Kate, Ferrara, Napoleone, Olsen, Bjorn, Clarkin, Claire E. , Paternoster, Lavinia , Kemp, John P. , Evans, David, TANG, JONATHAN C. Y. , Tobias, Jon H, Gregson, Celia Louise , Harvey, Nicolas, Orriss, Isabel R. , Ahmed, Faisal, Farquharson, Colin , MacRae, Vicky E. , Huesa, Carmen , Hof, Rob vanʼt , Goodyear, Carl S. , Thomas, Neil P. , Jeffery, Nathan S. , Breasail, Mícheál Ó , Reid, Ian R. , Horne, Anne M. , Mihov, Borislav , Bolland, Mark J , Delmestri, Antonella , Pinedo‐Villanueva, Rafael , Wilson, Peter, Hughes, Andrew, Bou–Gharios, George , Ward, Kate, Yamada, Hiroshi, Hashizume, Hiroshi , Tanaka, Sakae , Walker-Bone, Karen E , Knowles, Helen J. , Snelling, Sarah , Tobias, Jon H, Clark, Emma , Doube, Michael , Hutchinson, John R. , Shefelbine, Sandra J. , Dillon, Scott , Nudelman, Fabio , Kanczler, Janos M. , Schneider, Karl H. , Pollard, Andrea S. , Butterfield, Natalie C. , Williams, Graham R, Ahlfeld, Tilman , Glinka, Michael , Kim, Yang‐Hee , Yang, Shoufeng , Gelinsky, Michael , Wells, Julia A. , Kawaguchi, Hiroshi , Fisher, Matt, Miszkiewicz, Justyna Jolanta , Yoshimura, Takashi , Allen, Rebecca S. , El‐Jawhari, Jehan J. , Burska, Agata N. , Ponchel, Frédérique , Giannoudis, Peter Vasilios , Jones, Elena , Komla-Ebri, Davide S. K. , Hohenstein, Peter , Hung, John , Newby, David E. , Baker, Andrew, Karsenty, Gérard , Hsu, Shun‐Neng , Staines, Katherine Ann , Blain, Emma J. , Mason, Debbie, Rodriguez, Alexander, McMillan, Lachlan B. , Srikanth, Velandai , Ebeling, Peter R. , Javaheri, Behzâd , Ferrara, Napoleone, Olsen, Bjorn, Pitsillides, Andrew A. , Jones, Tim J , Clynes, Michael A. , James, Anthony , Harvey, Nicolas, Ersek, Adel , Cosulich, Carlotta Cecilia, Udalova, Irina A. , Horwood, Nicole J. , Jameson, Karen, Dennison, Elaine Margaret , Ayre, Wayne Nishio , Evans, Sam, Morgan, Stephanie, Mandair, Gurjit S. , Kohn, David H. , Kadamban, Premila, Galloway, James Benjamin , Vaughan-Lane, Tim, Wright, Maria, Brassett, Cecilia , Poole, Kenneth, Judge, Andrew , Leyland, Kirsten M. , Bourne, Lucie E. , Patel, Jessal J. , D’Haese, Patrick C. , Majonga, Edith D. , Mujuru, Hilda Angela , Ferrand, Rashida A. , Chen, Jiye , Dawson, Jonathan I. , Geng, Jin , Lim, Khoon S. , Woodfield, Tim B. F. , Greenwood, Charlene , Rogers, Keith D. , McGivern, Hannah , Márquez‐Grant, Nicholas , Zioupos, Peter , Hopkinson, Mark , Howat, David, Williams, Katherine A. , Gostling, Neil J. , Dyke, Gareth J. , Browne, Martin , Woods, Christopher, Dickinson, Alex , Zakrzewski, Sonia , Hartley, Chris, Folland, Jonathan P. , Brooke-Wavell, Katherine S. F. , Ossipov, Dmitri A. , Lu, William W. , Arden, Nigel , Edwards, James R., Kluzek, Stefan , Sanchez-Santos, Maria Teresa , Ismail, Omar Mohammad , Egan, Ben, Birchall, James C. , Heard, Charles, Marchi, Elena De , Virgilio, Francesco Di , Adinolfi, Elena , Gartland, Alison , Moura, Catarina Costa , Tare, Rahul S. , Xavier, Miguel , Beech, Jason Paul , Spencer, Daniel C. , Tegenfeldt, Jonas Olof , Morgan, Hywel , Murphy, Caitlin C. , Gregory, J.S. , Riemen, Anna H.K. , Davies, Amanda, Ahmad, Faizan , Theobald, Peter S. , Johnston, Richard, Piercy, Richard J. , Millar, Sophie , Anderson, Susan, O’Sullivan, Saoirse Elizabeth , Roberts, Scott, Jóhannesdóttir, Fjóla , Anderson, Dennis , Samelson, Elizabeth J , Kiel, Douglas P. , Nash, Thomas, Rochford, Justin J. , Al‐Sabah, Ayesha , Hardy, Rebecca

Mayo Clinic

JBMR Plus | October 2, 2018 | Volume: 2 | Issue: S1 | Pages: No page available

10.1002/jbm4.10073 Get It

Quantifying passive muscle stiffness in children with and without cerebral palsy using ultrasound shear wave elastography
Brandenburg, Joline E. , Eby, Sarah F. , Song, Pengfei , Kingsley‐Berg, Shirley, Bamlet, William R. , Sieck, Gary C. , An, Kai‐Nan, Bamlet, William, An, Kai‐Nan , Sieck, Gary , Bamlet, William R , Song, Pengfei

Mayo Clinic

Developmental Medicine & Child Neurology | July 4, 2016 | Volume: 58 | Issue: 12 | Pages: 1288-1294

10.1111/dmcn.13179 | PMID 27374483 Get It

AimThe aim of this study was to compare passive muscle stiffness in children with cerebral palsy (CP) and children with typical development using a novel ultrasound technique: ultrasound shear wave elastography (SWE).MethodWe conducted a prospective study of 13 children with CP (six females and seven males, median age 5y 1mo [interquartile range 4y 4mo–7y 8mo]) and 13 children with typical development (six females and seven males, median age 5y 3mo [interquartile range 4y 4mo–9y 4mo]). Demographic information and physical exam measurements were obtained in addition to shear modulus measurements (passive muscle stiffness) of the lateral gastrocnemius muscle at 20° plantar flexion, 10° plantar flexion, and 0° plantar flexion using SWE.ResultsChildren with CP had significantly greater shear modulus measurements at all three foot positions (p<0.050). When the shear modulus values were normalized to the baseline value for each child, there was no significant difference between the two groups.InterpretationPassive muscle stiffness, measured without the influence of spasticity, is greater in children with CP than in children with typical development when a muscle is at slack and at stretch. When shear modulus was normalized, the results indicate that muscle in children in both groups responds similarly to passive stretch. Further work includes evaluating effect of botulinum toxin on passive muscle properties.
Abstract A30: Integrated analysis of genomic data and annotations in cancer research
Ustach, Carolyn V., Han, Haiyong , Barret, Michael, Keats, Johnathan J., Hoff, Daniel D. Von , Kingsley, Christopher , Kim, Seungchan , Hostetter, Galen H. , Diep, Caroline H. , Hidalgo, Manuel

Mayo Clinic

Molecular Cancer Therapeutics | June 27, 2012 | Volume: 8 | Issue: 12_Supplement | Pages: A30-A30

10.1158/1535-7163.targ-09-a30 Get It

Abstract Many cancer researchers are currently generating heterogeneous genomic data sets containing mRNA expression, array based comparative genomic hybridization (aCGH), and other information from multiple patients. In the near future, data sets will likely include proteomics, methylomics, and high throughput sequencing data. Analytical tools that integrate these different data types to prioritize genes for further study have lagged, however. With this in mind, we have implemented a standalone software application that integrates CGH and mRNA expression profiling data. This application implements several different methods to generate ranked lists of genes and genomic regions based on breakpoint frequency, aberration frequency, and the impact of copy number changes on mRNA expression. The software is Java GUI based, with abstracted object models that can be extended as new genomic data types and annotations become available. We used this application to analyze aCGH datasets generated from 22 primary pancreatic tumor xenografts and mRNA expression datasets from 16 of the 22 samples. Genes which were located near a putative breakpoint and whose expression levels were high in a majority of the xenografts samples were considered putative targets. Preliminary IHC analysis of pancreas primary tumor tissue microarrays confirms one of these putative targets, Chemokine (CXC motif) Ligand 5 (CXCL5). By allowing cancer researchers to correlate genomic aberrations with expression data, we believe that this application will generate more meaningful targets for further biomarker identification and/or drug target discovery. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A30.
Local sensory nerve control of skin blood flow during local warming in type 2 diabetes mellitus
Strom, Nicholas A., Sawyer, Jessica R., Roberts, Shelly K., Kingsley‐Berg, Shirley M., Charkoudian, Nisha

Mayo Clinic

Journal of Applied Physiology | December 3, 2009 | Volume: 108 | Issue: 2 | Pages: 293-297

10.1152/japplphysiol.01077.2009 | PMID 19959764 Get It

Cutaneous sensory nerve-mediated vasodilation is an important component of normal microvascular responsiveness to thermal and nonthermal stimuli. Since both neural and microvascular function can be impaired in type 2 diabetes mellitus (T2DM), we tested the hypothesis that local sensory nerve-mediated vasodilation during nonpainful local warming of the skin is less in T2DM compared with healthy controls (C) matched for age and body size. The rapid vasodilation during the first ∼5 min of this local warming (“initial peak”) was previously shown to rely primarily on local sensory nerves. We measured skin blood flow in T2DM and C subjects ( n = 7 in each group) at baseline and during 35 min of local warming of the skin to 42°C at two sites on the ventral forearm. One site was pretreated with 4% lidocaine (LIDO) to block local sensory innervation. During local warming, cutaneous vascular conductance (CVC) during the initial peak was not different between groups, either at the untreated site [T2DM 75 ± 2 vs. C 81 ± 6% of maximum CVC (%maxCVC); P > 0.05] or at the LIDO site (T2DM 63 ± 7 vs. C 64 ± 6%maxCVC; P > 0.05). The difference between untreated and LIDO sites (sensory nerve contribution) was also similar between groups (T2DM 13 ± 5 vs. C 18 ± 5%maxCVC; P > 0.05) and was smaller with LIDO than was previously shown with other local anesthetics. Our results suggest that relatively healthy individuals with T2DM do not exhibit impairments in local sensory nerve vasodilation during thermal stimulation compared with controls of similar age and body size.
Tumor Necrosis Factor–Like Weak Inducer of Apoptosis Stimulation of Glioma Cell Survival Is Dependent on Akt2 Function
Ensign, Shannon P. Fortin , Ennis, Matthew, Savitch, Benjamin A., Carpentieri, David , McDonough, Wendy S., Winkles, Jeffrey A. , Loftus, Joseph C. , Kingsley, Christopher , Tran, Nhan L. , Ensign, Shannon P. Fortin , Hostetter, Galen H. , Carpentieri, David , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | October 28, 2009 | Volume: 7 | Issue: 11 | Pages: 1871-1881

10.1158/1541-7786.mcr-09-0194 | PMID 19861406 Get It

Abstract Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and significant technical advances in surgical and radiation treatment, the impact on clinical outcome for patients with malignant gliomas is disappointing. We have previously shown that tumor necrosis factor–like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival via binding to the Fn14 receptor, activation of the NF-κB pathway, and upregulation of BCL-XL gene expression. Here, we show that TWEAK treatment of glioma cells leads to phosphorylation of Akt and BAD. TWEAK stimulation results in the phosphorylation of both Akt1 and Akt2. However, small interfering RNA (siRNA)–mediated depletion of either Akt1 or Akt2 showed that BAD serine 136 phosphorylation is dependent specifically on Akt2 function. Depletion of Akt2 expression by siRNA also abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival was observed after siRNA-mediated depletion of Akt1 expression. Surprisingly, although siRNA-mediated depletion of BAD in glioma cells abrogates cytotoxic- and chemotherapy-induced apoptosis, TWEAK still displays a strong protective effect, suggesting that BAD serine 136 phosphorylation plays a minor role in TWEAK-Akt2–induced glioma cell survival. We also report here that AKT2 gene expression levels increased with glioma grade and inversely correlate with patient survival. Additionally, immunohistochemical analysis showed that Akt2 expression positively correlates with Fn14 expression in glioblastoma multiforme specimens. We hypothesize that the TWEAK-Fn14 signaling axis functions, in part, to enhance glioblastoma cell survival by activation of the Akt2 serine/threonine protein kinase. (Mol Cancer Res 2009;7(11):1871–81)